Tagged Articles

saxagliptin 13 articles

Large analysis of three clinical trials links diabetes drugs gliptins to acute pancreatitis

An analysis of three large clinical trials looking at the cardiovascular safety of three type 2 diabetes drugs known as gliptins has found that the medications significantly increase the risk of acute pancreatitis. The study, conducted by Ivan Tkac, M.D., Ph.D., from Pasteur University Hospital in Kosice, Slovakia, and Itamar Raz, M.D., from Hadassah Hebrew University Hospital in Jerusalem, combined incidence of acute pancreatitis from randomized controlled trials. The trials included SAVOR-TIMI 53, involving the medication Onglyza (saxagliptin); EXAMINE, involving the drug Nesina (alogliptin); and TECOS, involving the drug Januvia (sitagliptin). Combined, the studies involved 18,238 gliptin-treated patients and 18,157 ... Read More

New labels warn of new risks for diabetes drugs Nesnia, Onglyza

The safety labels for the type 2 diabetes drugs Nesnia (alogliptin) and Onglyza (saxagliptin) have been updated to include new warnings for pancreatitis and heart failure. Nesnia and Onglyza are in a newer class of type 2 diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. Other drugs in this class include Januvia (sitagliptin) and Tradjenta (linagliptin). The “Warnings and Precautions” section for both Nesnia and Onglyza now include a warning that in post-marketing settings and/or randomized clinical trials, patients have been diagnosed with acute pancreatitis. Pancreatitis is a painful inflammation of the pancreas that can increase the risk for more ... Read More

Type 2 diabetes drugs linked to cancer spread

Two widely used type 2 diabetes drugs, which are also antioxidants, appear to stimulate cancer metastasis in laboratory mice, a new study has found. The research narrowed in on antioxidants and the popular notion that adding them to the diet can prevent cancer, slow aging as well as a slew of other health benefits. Granted, antioxidants found in foods like fruits and vegetables have been found to neutralize free radicals that can damage DNA, which can lead to cancer. This idea has fostered the belief that antioxidants can also prevent cancer. But, studies on antioxidant pills sold as dietary supplements ... Read More

Some type 2 diabetes drugs linked to heart failure

Drugs from a new class of type 2 diabetes treatments, including Onglyza, Kombiglyze XR and Nesina, have been linked to heart failure, and patients with heart or kidney disease are even more susceptible to this risk, the Food and Drug Administration (FDA) warned in a Safety Alert. The risk was seen with the drug ingredient saxagliptin (found in Onglyza and Kombiglyze XR) and alogliptin (found in the brands Nesina, Kazano and Oseni). Both saxagliptin and alogliptin are in a newer class of type 2 diabetes drugs known as dipeptidyl peptidase-4 (DPP-4) inhibitors. The new warning comes after an FDA review ... Read More

FDA opens investigation into heart failure risk with diabetes drugs Onglyza, Kombiglyze

The Food and Drug Administration (FDA) has opened an investigation into the safety of the type 2 diabetes drug saxagliptin after a recent study published in the New England Journal of Medicine (NEJM), reported an increased rate of hospitalizations for heart failure in patients taking the drug. Heart failure occurs when the heart does not efficiently pump blood throughout the body. It can lead to more serious and life threatening problems. Saxagliptin is sold in the United States under the brand names Onglyza and Kombiglyze XR. Patients currently taking saxagliptin should talk with their health care providers about any questions ... Read More

Clinical trials to begin on novel new type 2 diabetes drug

Zydus Cadila Healthcare has been given approval by the Food and Drug Administration (FDA) to begin phase I clinical trials of ZYDPLA1, a novel next generation orally active small molecule DPP-4 inhibitor to treat type 2 diabetes. ZYDPLA1 is a New Chemical Entity (NCE), a classification given to a drug that contains no active functioning group that has been approved by the FDA in any other application. The drug was discovered and developed by the Zydus Research Center. It is a novel compound in the Gliptin class of diabetes medications, also known as DPP-4 inhibitors. ZYDPLA1 works by blocking the enzyme ... Read More

Diabetes drugs may not increase heart problems but could pose cancer risk

Studies involving different type 2 diabetes drugs show no evidence that the medications cause heart attacks and strokes, however they do not improve cardiovascular outcomes in patients either. Some medications also pose cancer risks. The first study compared the drug saxagliptin, marketed in the United States as Onglyza, with a placebo in patients who had type 2 diabetes and were considered at high risk for a cardiovascular event. Another study pitted the drug alogliptin, marketed as Nesina, against placebo. Researchers recorded incidences of cardiovascular death, heart attack or ischemic stroke as well as hospitalizations for unstable angina, coronary revascularization or ... Read More

Some type 2 diabetes medications linked to increased risk of heart failure

New studies suggest two type 2 diabetes drugs do not increase the risk of heart attack, but may increase the risk of heart failure. A heart attack occurs when blood flow to part of the heart is blocked for a long enough time to cause damage or death to part of the heart muscle. Heart failure is a condition in which the heart cannot pump enough blood to the rest of the body. Both conditions can be deadly. Cardiovascular risks with diabetes medications have made headlines in recent years since the blockbuster diabetes drug Avandia was linked to fatal heart ... Read More

Diabetes drug Tradjenta linked to acute pancreatitis, fatal pancreatitis

The safety label for the type 2 diabetes treatment Tradjenta (linagliptin) has been updated to warn that there have been reports of acute pancreatitis, including fatal pancreatitis, in patients taking the medication. Doctors and patients are advised to take special note of potential signs and symptoms of pancreatitis, and if the condition is suspected, to discontinue Tradjenta and initiate appropriate management. It is unknown whether patients with a history of pancreatitis are at an increased risk for developing the condition while using the drug. Tradjenta is an oral medication that is designed to reduce blood sugar levels in patients with ... Read More

Type 2 diabetes drug does not reduce risk of heart attack, stroke, death

Diabetes drug Onglyza (saxagliptin) does not reduce the risk of heart attacks, strokes or death from cardiovascular causes compared to a placebo, drug makers Bristol Myers Squibb and AstraZeneca said. The companies had conducted clinical trials to determine if the Type 2 diabetes treatment could help reduce the risk of non-fatal heart attacks and ischemic strokes and death from cardiovascular problems as well as lower blood glucose levels. Onglyza did not perform better than a placebo; however, it was not inferior to the placebo either. The clinical trials involved 16,500 people with diabetes as well as a history of heart ... Read More